MEDIUM confidence: 100% data completeness, but the composite (39) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net insider -$11.8M over 180 days (0 open-market buys, 49 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $735 avg across 5 analysts.
Buy-rated share 88% → 95% over ~3 months (+7pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $-2.68 | $-1.99 | +25.7% |
| May 2026 | $-3.61 | $-3.25 | +10.0% |
| Feb 2026 | $0.04 | $-2.57 | -6525.0% |
| Nov 2025 | $-2.04 | $-5.08 | -149.4% |
| Aug 2025 | $-3.48 | $-1.90 | +45.4% |
| May 2025 | $-3.62 | $-3.32 | +8.3% |
| Feb 2025 | $-4.32 | $-2.71 | +37.3% |
| Oct 2024 | $-6.94 | $-4.92 | +29.1% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0— | $0n/m | $0n/m | $180Mn/m | $958M+432.1% |
| EPS (dil.) | $-14.63— | $-17.23n/m | $-19.99n/m | $-21.90n/m | $-12.85n/m |
| Free Cash Flow | -$184M— | -$225Mn/m | -$326Mn/m | -$457Mn/m | -$190Mn/m |
| Gross Margin | — | — | — | 96.5% | 94.1%-2.4pp |
| Operating Margin | — | — | — | -276.4% | -31.3%+245.1pp |
| Net Margin | — | — | — | -258.6% | -30.1%+228.6pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 39 for Madrigal Pharmaceuticals indicates a neutral outlook, driven by a strong growth profile, with revenue growth of 432.1% and EPS growth of 41.3%, but offset by poor value and profitability metrics, including a negative P/E and ROE of -56.6%. The stock trades at a premium, with high price multiples, and exhibits weak momentum, having declined 10.4% over the past three months. The long-term and short-term scores are relatively aligned, with only a 3-point difference, suggesting a consistent view across different time horizons.